markettrend766
30-09-2008, 09:49 PM
DEAR MEMBERS
Aditya Birla group possibly will buy 50 per cent of Hindalco Industries rights issue by buying the unsold shares. Hindalco's Rs 5047.70 crore issue opened on Sep 22 and will closes on Oct 10. If Aditya Birla Group buys the unsold shares, their stake in the company will increase to 37 per cent from 31.43 per cent.
Reliance Communications on Sunday soft-launched its global systems for mobile communications (GSM) network across the major cities like Mumbai, Delhi and Punjab etc. It's learnt that Rcom has invested about Rs 800 crore each in Mumbai and Delhi.
Cancer drug maker Natco Pharma Ltd, which had filed the country’s first compulsory licence application, withdrew its plea on September 26. Natco has asked India’s patents regulator controller general of patents, designs and trademarks, to drop the petition, said media reports. The application had sought permission to manufacture and export copy versions of two patented drugs: F Hoffman La Roche Ltd’s lung cancer drug Tarceva, and Pfizer Inc.’s kidney cancer drug Sutent.
Sun Pharmaceuticals continues its focus on the US with new vigour. Sun generates 41 per cent of its annual revenues from the US market. The company is bullish on its US prospects and expects 25 per cent growth in the country this year, higher than the 18-20 per cent growth projection it has given for other markets including India. Sun Pharma shares settled at Rs 1466.05 on BSE Friday, down 0.53 per cent.
Aditya Birla group possibly will buy 50 per cent of Hindalco Industries rights issue by buying the unsold shares. Hindalco's Rs 5047.70 crore issue opened on Sep 22 and will closes on Oct 10. If Aditya Birla Group buys the unsold shares, their stake in the company will increase to 37 per cent from 31.43 per cent.
Reliance Communications on Sunday soft-launched its global systems for mobile communications (GSM) network across the major cities like Mumbai, Delhi and Punjab etc. It's learnt that Rcom has invested about Rs 800 crore each in Mumbai and Delhi.
Cancer drug maker Natco Pharma Ltd, which had filed the country’s first compulsory licence application, withdrew its plea on September 26. Natco has asked India’s patents regulator controller general of patents, designs and trademarks, to drop the petition, said media reports. The application had sought permission to manufacture and export copy versions of two patented drugs: F Hoffman La Roche Ltd’s lung cancer drug Tarceva, and Pfizer Inc.’s kidney cancer drug Sutent.
Sun Pharmaceuticals continues its focus on the US with new vigour. Sun generates 41 per cent of its annual revenues from the US market. The company is bullish on its US prospects and expects 25 per cent growth in the country this year, higher than the 18-20 per cent growth projection it has given for other markets including India. Sun Pharma shares settled at Rs 1466.05 on BSE Friday, down 0.53 per cent.